The augmentation of the user base is estimated to add to the development of the artificial cervical device market. The market's report is efficiently analyzed as per MRFR, which provides outlooks for the global markets. The income of USD 6,262.1 million is estimated to be attained at a CAGR of 19% by 2027.

The advancements in artificial discs are estimated to add momentum to their demand in the duration of the forecast period. Furthermore, the supportive reimbursement policies available in several regions are estimated to bolster the artificial cervical device market share in the coming period.

Segmental Analysis

The segmental overview of the artificial cervical device market is conducted on the basis of product, material, region, and end user. The product type segment of the artificial cervical device market comprises of lumbar disc and cervical disc. The material segment of the artificial cervical device market comprises of metal-on-metal and metal-on-biopolymer. The region segment of the artificial cervical device market comprises of North America, Europe, Asia-Pacific, and other significant regions. The end user segment of the artificial cervical device market comprises of hospitals and ambulatory surgical centers.

Regional Overview

The regional scrutiny of the artificial cervical device market comprises of North America, Europe, Asia-Pacific, and other significant regions. The artificial cervical disc market in North America is being driven by an expanding geriatric population and a higher success rate of artificial disc replacement surgeries across the region. Due to the noticeable growing senior population, higher success rates of artificial disc replacement surgery, and growing awareness among patients about the availability of various treatment choices, North America is predicted to have the greatest share of the global artificial cervical disc market. Due to quickly improving medical infrastructure, rising healthcare spending, a big population, and growing medical tourism in developing countries such as China, Japan, and India, Asia-Pacific is expected to grow quickly throughout the projection period.

Competitive Analysis

The requirement to effectively engage clients in all the geographical areas is expected to aid the market in overcoming the current challenges. The necessity to develop a competitive advantage over its competitors has a significant impact on the global market. With a combination of innovation and continuous product refinement, the market is expected to lead its future expansion. The current market trends are making a significant contribution to the industry's growth. The market contenders are expected to promote growth enabling elements and, as a result, to bring the market out of the current worldwide pandemic. During the predicted period, the focus on accelerated growth is expected to take center stage. The use of technology and a strategy-based approach is likely to increase the likelihood of future success. The market's heightened focus on high-revenue decision-making is expected to hasten its return to normalcy in the coming months. Furthermore, the market stakeholders need to ensure that long-term sustainable growth targets are not endangered due to current difficulties.

The eminent contenders in the artificial cervical device market are Zimmer Biomet Holdings Inc. (US), Centinel Spine, LLC (Switzerland), Braun Melsungen AG (Germany), Medicrea (France), Medtronic PLC (Ireland), Nuvasive Inc. (US), Johnson & Johnson (US), Orthofix Company (US), Alphatec Spine (US), Simplify Medical (US), Globus Medical Inc (US), AxioMed (US), Aditus Medical (Germany), FH Orthopedics (France), and Spineart (Switzerland).

Industry Updates:

Aug 2021 Orthofix Medical Inc., a global medical device company focused on spine and orthopedics, announced the first patient implant in a US Food and Drug Administration clinical study comparing the M6-C artificial cervical disc to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy. Patients will be enrolled in both the M6-C therapy and the ACDF control groups at the same time. According to their site group, 263 patients will receive a two-level cervical artificial disc treatment or an instrumented ACDF procedure for the trial.

Apr 2021 NuVasive's Simplify Cervical Artificial Disc has been approved by the FDA for use in two-level cervical total disc replacement (cTDR) surgeries. In a two-level Investigational Device Exemption (IDE) study, the Simplify Disc demonstrated clinical superiority at 24 months compared to anterior cervical discectomy and fusion (ACDF) alternatives, as well as a higher overall clinical success rate than any other approved cervical disc at both one- and two-levels, according to the US medical device company.